Biopharmaceutical company Gilead Sciences has entered a definitive agreement to acquire US-based Kite Pharma for approximately $11.9bn.

Kite Pharma specialises in the development of new cell therapies, which use a patient’s own immune cells to combat cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The current transaction will offer opportunities for diversification of revenues and was unanimously approved by the boards of directors of both companies.

Gilead Sciences president and chief executive officer Dr John F. Milligan said: “The acquisition of Kite establishes Gilead as a leader in cellular therapy and provides a foundation from which to drive continued innovation for people with advanced cancers.”

The transaction will be financed with a combination of cash on hand, bank debt and senior unsecured notes, and is expected to conclude in the fourth quarter of this year.

"CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers."

Kite Pharma has created engineered cell therapies that express either a chimeric antigen receptor (CAR) or an engineered T-cell receptor (TCR), based on the type of cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s primary CAR T therapy candidate, axicabtagene ciloleucel (axi-cel), is expected to be the first available treatment for refractory aggressive non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL).

Kite Pharma president, chairman and CEO Dr Arie Belldegrun said: “CAR T has the potential to become one of the most powerful anti-cancer agents for hematologic cancers.”

Axicabtagene ciloleucel is currently under priority review by the US Food and Drug Administration (FDA).

A marketing authorisation application (MAA) has also been filed with the European Medicines Agency (EMA) for axi-cel for the treatment of relapsed / refractory DLBCL, TFL and PMBCL.

The approval in Europe is expected in 2018.